Doddy Irawan Setyo Utomo
Research Subjects
Doddy Irawan Setyo Utomo has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Astutiati Nurhasanah
Centre for Vaccine and Drug Research, National Research and Innovation Agency Republic of Indonesia, Kawasan Puspiptek Serpong, Serpong, 15314
2 shared publications - Masteria Yunovilsa Putra
National Research and Innovation Agency
2 shared publications - Asep Bayu
Research Center for Vaccine and Drug, National Research and Innovation Agency (BRIN), Bogor, Indonesia
1 shared publication Debora Christin Purbani
Research Center for Biosystematics and Evolution, National Research and Innovation Agency (BRIN), Bogor, Indonesia
1 shared publicationDiah Radini Noerdjito
Research Center for Biosystematics and Evolution, National Research and Innovation Agency (BRIN), Bogor, Indonesia
1 shared publication- Dwi Wahyu Indriani
Research Center for Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), Bogor, Indonesia
1 shared publication
Latest Publications
- Open Access
- 30 August 2026
- Published by Springer Nature in AMB Express
Heterologous expression of recombinant dengue virus C-prM-E structural antigens from all four serotypes in the red microalga Porphyridium purpureum
The dengue virus (DENV) remains a significant global health threat, and the currently available vaccines exhibit concerns regarding safety, efficacy, and cost-effectiveness. Microalgae represent an innovative method for producing proteins that do not occur naturally. They are Generally Recognized As Safe (GRAS), easily scalable, and capable of inducing post-translational modifications in eukaryotes. This study illustrates the effective heterologous expression of recombinant dengue virus capsid–premembrane–envelope (C-prM-E) structural antigen constructs representing all four DENV serotypes (DV1–DV4) in the red microalga Porphyridium purpureum through Agrobacterium tumefaciens -mediated transformation. Gene constructs containing capsid-premembrane-envelope (CprME) polyprotein fragments with C-terminal epitope tags were cloned into pCAMBIA1301 vectors and subsequently introduced into P. purpureum . PCR amplification confirmed the successful chromosomal integration of all four serotype constructs, yielding the anticipated 2.5-kb amplicons. The SDS-PAGE analysis revealed protein bands at around 85 kDa, consistent with the expected molecular weight of the processed CprME-derived proteins. We employed both anti-DENV-2 and anti-FLAG antibodies in a western blot assay to demonstrate that the recombinant antigens were identical and interacted with the immune system across all serotypes. These findings indicate that P. purpureum is an effective system for expressing DENV antigens, paving the path for the development of cost-effective, plant-derived dengue vaccine candidates. This microalgal platform may facilitate the large-scale production of tetravalent dengue vaccines, particularly in regions where dengue is prevalent and resources are scarce.
- 30 August 2026
- Published by Springer Nature in AMB Express
Open AccessHeterologous expression of recombinant dengue virus C-prM-E structural antigens from all four serotypes in the red microalga Porphyridium purpureum
The dengue virus (DENV) remains a significant global health threat, and the currently available vaccines exhibit concerns regarding safety, efficacy, and cost-effectiveness. Microalgae represent an innovative method for producing proteins that do not occur naturally. They are Generally Recognized As Safe (GRAS), easily scalable, and capable of inducing post-translational modifications in eukaryotes. This study illustrates the effective heterologous expression of recombinant dengue virus capsid–premembrane–envelope (C-prM-E) structural antigen constructs representing all four DENV serotypes (DV1–DV4) in the red microalga Porphyridium purpureum through Agrobacterium tumefaciens -mediated transformation. Gene constructs containing capsid-premembrane-envelope (CprME) polyprotein fragments with C-terminal epitope tags were cloned into pCAMBIA1301 vectors and subsequently introduced into P. purpureum . PCR amplification confirmed the successful chromosomal integration of all four serotype constructs, yielding the anticipated 2.5-kb amplicons. The SDS-PAGE analysis revealed protein bands at around 85 kDa, consistent with the expected molecular weight of the processed CprME-derived proteins. We employed both anti-DENV-2 and anti-FLAG antibodies in a western blot assay to demonstrate that the recombinant antigens were identical and interacted with the immune system across all serotypes. These findings indicate that P. purpureum is an effective system for expressing DENV antigens, paving the path for the development of cost-effective, plant-derived dengue vaccine candidates. This microalgal platform may facilitate the large-scale production of tetravalent dengue vaccines, particularly in regions where dengue is prevalent and resources are scarce.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Veterinary Science
- Vol. 27 (3) , e16
Advances in African swine fever vaccine development: challenges and prospects
Utomo DI, et al. J Vet Sci. 2026 Jan;27:e16. https://doi.org/10.4142/jvs.25160
- 1 January 2026
- Published by XMLink in Journal of Veterinary Science
- Vol. 27 (3) , e16
Open AccessAdvances in African swine fever vaccine development: challenges and prospects
Utomo DI, et al. J Vet Sci. 2026 Jan;27:e16. https://doi.org/10.4142/jvs.25160
- Open Access
An Overview of Recent Developments in the Application of Antigen Displaying Vaccine Platforms: Hints for Future SARS-CoV-2 VLP Vaccines
Recently, a great effort has been devoted to studying attenuated and subunit vaccine development against SARS-CoV-2 since its outbreak in December 2019. It is known that diverse virus-like particles (VLPs) are extensively employed as carriers to display various antigenic and immunostimulatory cargo modules for vaccine development. Single or multiple antigens or antigenic domains such as the spike or nucleocapsid protein or their variants from SARS-CoV-2 could also be incorporated into VLPs via either a genetic or chemical display approach. Such antigen display platforms would help screen safer and more effective vaccine candidates capable of generating a strong immune response with or without adjuvant. This review aims to provide valuable insights for the future development of SARS-CoV-2 VLP vaccines by summarizing the latest updates and perspectives on the vaccine development of VLP platforms for genetic and chemical displaying antigens from SARS-CoV-2.
Open AccessAn Overview of Recent Developments in the Application of Antigen Displaying Vaccine Platforms: Hints for Future SARS-CoV-2 VLP Vaccines
Recently, a great effort has been devoted to studying attenuated and subunit vaccine development against SARS-CoV-2 since its outbreak in December 2019. It is known that diverse virus-like particles (VLPs) are extensively employed as carriers to display various antigenic and immunostimulatory cargo modules for vaccine development. Single or multiple antigens or antigenic domains such as the spike or nucleocapsid protein or their variants from SARS-CoV-2 could also be incorporated into VLPs via either a genetic or chemical display approach. Such antigen display platforms would help screen safer and more effective vaccine candidates capable of generating a strong immune response with or without adjuvant. This review aims to provide valuable insights for the future development of SARS-CoV-2 VLP vaccines by summarizing the latest updates and perspectives on the vaccine development of VLP platforms for genetic and chemical displaying antigens from SARS-CoV-2.